Influenza: Current evidence and informed predictions

Expert Review of Vaccines

Volumn 3, Issue 4, 2004, Pages 443-451

  Handa, Ritu ^a   Teo, S ^a   Booy, Robert ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Antiviral; Immunization; Influenza; Vaccine

Indexed keywords

AMANTADINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; LYSOVIR; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ADULT; CHILD; CHILL; DEATH; DIZZINESS; DRUG EFFICACY; ENCEPHALITIS; FALLING; FEBRILE CONVULSION; FEVER; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HALLUCINATION; HEADACHE; HEALTH PROGRAM; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INSOMNIA; MYALGIA; MYOCARDITIS; MYOSITIS; NAUSEA; NEUROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UNITED STATES; VERO CELL; VOMITING; WINTER;

HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 4043123311     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.443     Document Type: Review

References (56)

1. Goddard NL, Joseph CA, Watson JM, Ellis JS, Zambon MC. Three years of low influenza activity - no reason for complacency. Commun. Dis. Public Health 6, 128-132 (2003).
2. Izurieta HS, Thompson WW, Kramarz P et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med. 342, 232-239 (2000).
3. Gamblin SJ, Haire LF, Russell RJ et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303, 1838-1842 (2004).
4. Webster RG, Hay AJ. The H5N1 influenza outbreak in Hong Kong: a test of pandemic preparedness. In: Textbook of influenza. Blackwell Scientific Publications, London, UK, 561-565 (1998).
5. Centres for Disease Control and Prevention. Guideline for infectious control in healthcare personnel, 1998. Infect. Control Hosp. Epidemiol. 19, 410-459 (1998).
6. Long CE, Hall CB, Cunningham CK et al. Influenza surveillance in community-dwelling elderly compared with children. Arch. Fam. Med. 6, 459-465 (1997).
7. Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population on the course of an A2/Hong Kong influenza epidemic. Bull. World Health Org. 41, 537-542 (1969).
8. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am. J. Epidemiol. 115, 736-751 (1982).
9. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 21, 1762-1768 (2003).
10. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur. Heart J. 25, 25-31 (2004).
11. Nichol KL, Nordin J, Mullooly J et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke in the elderly. N. Engl. J. Med. 348, 1322-1332 (2003).
12. Hak E, Nordin J, Wei F et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin. Infect. Dis. 35, 370-377 (2002).
13. Loughlin J, Poulis N, Napalkov P, Wegmuller Y, Monto AS. A study of influenza-related complications among children in a large US health insurance plan database. Pharmacoeconemics 21, 273-283 (2003).
14. Morishima R, Togashi T, Yokota S et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin. Infect. Dis. 35, 512-517 (2002).
15. Weinburg GA, Erdman DD, Edwards KM et al. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J. Infect. Dis. 189, 706-710 (2004).
16. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 69, 517-528 (1992).
17. Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults. In: The Cochrane library, Issue 4. John Wiley and Sons Ltd, Chichester, UK (2001).
18. Freund B, Gravenstein S, Elliot M, Miler I. Zanamivir: a review of clinical safety. Drug Safety 4, 267-281 (1999).
19. Murphy KR, Eivindson A, Pauksens K et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin. Drug Invest. 20, 337-349 (2000).
20. Cooper NJ, Sutton AJ, Abrams KR et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized controlled trials. Br. Med. J. 326, 1235 (2003).
21. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20, 127-133 (2001).
22. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 21, 1776-1779 (2003).
23. Palashe AM, Scheepers HSJ, De Regt V et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. 98, 115-125 (1999).
24. Wagner DK, Clements ML, Reimer CB et al. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 25, 559-562 (1987).
25. Beyer WEP, Palache AM, de Jong JC, Osterhaus ADME. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20, 1340-1353 (2002).
26. Lasky T, Terracciano GJ, Magder L et al. The Guillain-Barré syndrome and the 1993 and 1993-1994 influenza vaccines. N. Engl. J. Med. 339, 1797-1802 (1998).
27. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 248, 698-700 (1982).
28. Mbawuike IN, Piedra PA, Cate TR, Couch RB. Cytotoxic T-lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine. J. Med. Virol 50, 105-111 (1996).
29. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20, 1831-1836 (2002).
30. Heikkinen T, Ruuskanen O, Waris M et al. Influenza vaccination in the prevention of acute otitis media in children. Am. J. Dis. Child. 145, 445-448 (1991).
31. Neuzil KM, DuPont WD, Wright PF, Edwards KM. Efficay of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experiences. Pediatr. Infect. Dis. J. 20, 733-740 (2001).
32. Maeda T, Shintani Y, Nakano K, Terashima K, Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6-24 months. Pediatr. Intl 46, 122 (2004).
33. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20, 2562-2578 (2002).
34. Nichol KL, Wuornema J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch. Intern. Med. 158, 1769-1776 (1998).
35. White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school aged children. Pediatrics 103, E73 (1999).
36. Fitner KA, Shortridge KF, McGhee SM, Hedley AJ. Cost-effectiveness study on influenza prevention in Hong Kong. Health Policy 56, 215-234 (2001).
37. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatrics 136, 168-175 (2000).
38. Piedra PA. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. Semin. Pediatr. Infect. Dis. 13, 90-96 (2002).
39. Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110, 62-72 (2002).
40. Wright PF, Karzon DT. Live attenuated influenza vaccines. Prog. Med. Virol. 34, 70-88 (1987).
41. Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated, intranasal influenza virus vaccine in healthy, adult workers: a randomized controlled trial. JAMA 282, 137-144 (1999).
42. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med. 338, 1405-1412 (1998).
43. Update: Influenza activity - United States, 1997-98 season. MMWR Weekly 47, 196-200 (1998).
44. Powers DC, Fries LF, Murphy BR, Thumar B, Clements ML. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccines in inducing serum or secretory antibodies or local immunological memory. J. Clin. Microbiol. 29, 498-505 (1991).
45. Targonski PV, Poland GA. Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly? Drugs Aging 21, 349-359 (2004).
46. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a nonadjuvanted influenza vaccine in nonelderly adults. Vaccine 21, 4234-4237 (2003).
47. Banzhoff A, Nacci P, Podda A. A new MF59 adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49, 177-184 (2003).
48. Bungener L, Idema J, ter Veer W et al. Virosomes in vaccine development induction of cytotoxic T-lymphocyte activity with virosome-encapsulated protein antigens. J. Liposome Res. 12, 155-163 (2002).
49. De Bruijn IA, Nauta J, Gerez L, Palache AM. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low prevaccination antibody titers. Virus Res. 103, 139-145 (2004).
50. Pregliasco F, Mensi C, Serpilli W et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano). 13, 38-43 (2001).
51. Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNA. Proc. Natl Acad. Sci. USA 96, 9345-9350 (1999).
52. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732-1737 (2001).
53. Krug RM. The potential use of influenza virus as an agent for bioterrorism. Antiviral Res. 57, 147-150 (2003).
54. Montagnon BJ, Fanget B, Nicholas AJ. The large-scale cultivation of Vero cells in microcarrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 47-55 (1987).
55. Bruhl P, Kerschbaum, Kistner O et al. Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine. Vaccine 19, 1149-1158 (2001).
56. Kroeman M, Paget WJ, van Essen GA. Influenza vaccination in Europe: an inventory of strategies to reach target populations and optimise vaccination uptake. Euro. Surveill. 8, 130-138 (2003).